PREFER

Developing recommendations

The point of PREFER is to develop evidence-based recommendations on how and when to include patient perspectives on benefits and risks of medicinal products.  The aim is to support development of guidelines for industry, Regulatory Authorities and HTA bodies.

We begin by defining the scope of the recommendations and preparing operational requirements and best practices for conducting clinical case studies. By the middle of 2019, we will have drafted recommendations and asked stakeholder advisory groups to test them to see how they work for other disease areas and decision points. By the middle of 2021 we expect to have a refined draft. Final recommendations will be presented in the autumn of 2021.

Our recommendations will be based on the results of our work with methodology and clinical case studies.

Find out who is doing the work

Progress

defining the scope of the recommendations

Operational requirements and best practices for conducting case studies